Astrogen Wins International Psychiatry Honor for Autism Clinical Trial Research, Strengthening Momentum for Speragen’s Global Development
Astrogen, Inc., a South Korean biotechnology company focused on developing therapies for neurodevelopmental disorders, has earned international recognition for its autism spectrum disorder clinical research after receiving the prestigious Folia Award from Psychiatry and Clinical Neurosciences (PCN). The honor was awarded for the company’s clinical trial paper evaluating AST-001, also known as Speragen Syrup, in children with autism spectrum disorder (ASD), underscoring the growing visibility of Astrogen’s research in the global psychiatric and neuroscience community.
The Folia Award is presented annually by Psychiatry and Clinical Neurosciences, an internationally recognized psychiatric journal published by the Japanese Society of Psychiatry and Neurology (JSPN), to the most outstanding paper published in the journal during the year. By selecting Astrogen’s study for this distinction, the PCN Editorial Committee has placed the company’s autism research among the most notable contributions to psychiatric science published by the journal, highlighting both the clinical relevance of the findings and the broader importance of advancing evidence-based treatments for children with ASD.
For Astrogen, the award represents more than a symbolic accolade. It serves as a strong external validation of the company’s scientific work at a time when it is seeking to move Speragen through the regulatory process in South Korea and accelerate development and commercialization efforts in other markets, including Japan. It also reinforces the significance of autism research in a field where therapeutic options remain limited and where families, clinicians, and researchers continue to search for interventions that can address core symptoms and improve long-term outcomes for affected children.
Award Recognizes Landmark Clinical Trial in Autism Spectrum Disorder
The paper that received the honor was titled “AST-001 versus placebo for social communication in children with autism spectrum disorder: A randomized clinical trial.” It was published in January 2025 in Psychiatry and Clinical Neurosciences (Volume 79, Issue 1). The study evaluated the efficacy and safety of AST-001, Astrogen’s investigational treatment branded as Speragen Syrup, in children diagnosed with autism spectrum disorder.
The research was led by Professor Hyo-Won Kim of Asan Medical Center and Professor Yoo-Sook Joung of Samsung Medical Center, reflecting a collaboration between Astrogen and leading Korean clinical experts in child and adolescent psychiatry. Importantly, the study was designed as a randomized controlled trial, or RCT, which remains one of the most rigorous methods for evaluating whether a treatment produces meaningful clinical benefit while maintaining an acceptable safety profile.
That methodological rigor likely contributed to the paper’s recognition by the PCN Editorial Committee. In psychiatry and neurodevelopmental research, where treatment effects can be complex and difficult to measure, well-designed randomized controlled studies are especially valuable. They provide a higher level of evidence than observational or exploratory work and can play a critical role in shaping regulatory decisions, clinical practice, and future research priorities.
By selecting Astrogen’s paper as the winner of the 18th Folia Award (2025), the editorial committee signaled that the study made a notable contribution to psychiatric and neuroscience literature. The award included a prize of 100,000 Japanese yen, but its significance extends well beyond the monetary component. Recognition from a respected international journal and a major psychiatric society provides Astrogen with scientific credibility that may prove valuable as the company continues to pursue regulatory review and strategic expansion.
International Recognition from a Respected Psychiatric Journal
Psychiatry and Clinical Neurosciences has long been regarded as an influential publication in psychiatry, psychology, and neuroscience research, particularly across Asia but also within the broader international psychiatric community. As the official journal of the Japanese Society of Psychiatry and Neurology, it serves as a platform for research spanning psychiatric disorders, neurobiological mechanisms, therapeutic interventions, and clinical innovations.
The Folia Award is therefore not simply a routine publication honor. It is a distinction conferred on a paper judged to be the most outstanding among all articles published by the journal during the relevant year. In Astrogen’s case, the recognition places its autism study at the center of current discussions in psychiatric research and highlights the increasing attention being paid to treatment innovation in autism spectrum disorder.
This is particularly meaningful because ASD remains an area of high unmet need. While there are therapies and interventions aimed at supporting communication, behavior, and development, there are still relatively few pharmacologic options that directly target the core social communication difficulties associated with autism. Any study suggesting progress in this area naturally attracts significant scientific and clinical interest, especially when supported by a randomized trial design and published in a reputable journal.
For Astrogen, the award also reinforces its status as a Korean biotech company capable of producing research that resonates beyond its domestic market. In an increasingly global biopharmaceutical environment, such recognition can support the company’s reputation among regulators, clinicians, academic collaborators, and potential commercial partners.
Recognition Extended at Major Japanese Psychiatry Conference
The honor was formally acknowledged at the 122nd Annual Conference of the Japanese Society of Psychiatry and Neurology, held in Yokohama, Japan, from June 18 to June 20, 2026. Astrogen’s research team was invited to the conference in connection with the award, providing the company with a high-profile opportunity to present its work to psychiatrists, researchers, and healthcare professionals from across Japan and the broader region.
Representing Astrogen at the meeting was Chief Executive Officer Hwang Su-gyeong, who played a central role in leading the company’s research efforts. During the event, Hwang delivered the official Award Lecture, presenting the key findings of the AST-001 clinical trial and discussing the broader clinical implications of the research.
That presentation carried strategic importance on several levels. First, it allowed Astrogen to showcase its data directly to a specialized audience deeply engaged in psychiatric and neurodevelopmental care. Second, it strengthened the company’s visibility in Japan, which Hwang described as a strategically important market for Astrogen’s future growth. And third, it positioned Speragen not only as a Korean development-stage therapy but as a candidate with growing recognition in one of Asia’s most sophisticated psychiatric and pharmaceutical markets.
Conference lectures tied to major journal awards often serve as an extension of the publication itself, helping to amplify the study’s reach and influence. By presenting the findings at a respected annual psychiatric meeting, Astrogen gained an additional platform to highlight the therapeutic potential of AST-001 and to engage with clinicians and researchers who may play a role in its future development or adoption.
Speragen Moves Forward Amid Regulatory Review in South Korea
Astrogen’s award arrives at a pivotal moment for the company’s lead program. According to Hwang, Speragen has already been submitted for product approval to South Korea’s Ministry of Food and Drug Safety (MFDS), and the company is currently awaiting the outcome of that regulatory review.
That timing makes the Folia Award especially significant. While regulatory authorities make decisions based on scientific, clinical, and manufacturing evidence rather than journal prizes, independent recognition from a respected psychiatric publication can still enhance the broader perception of a therapy’s scientific foundation. It can strengthen confidence among investors, physicians, and potential partners, while also helping to elevate awareness of the product in key markets.
Hwang noted that Astrogen hopes the award will have a positive impact on Speragen’s development and approval pathway. The comment reflects the broader reality that momentum matters in biotechnology. A therapy under review benefits not only from strong data but also from visibility, credibility, and sustained interest from the medical community. Recognition such as the Folia Award can help create that momentum by emphasizing that the therapy’s supporting research has already attracted meaningful international attention.
If Speragen ultimately secures approval in South Korea, the product could represent an important step forward for Astrogen as it transitions from a clinical-stage biotech company into a commercial organization. It would also be a notable development in the autism treatment landscape, particularly if the therapy demonstrates a clinically meaningful effect on social communication in pediatric patients.
Japan Emerges as a Strategic Commercialization Target
In discussing the award, Hwang made clear that Japan is one of Astrogen’s key strategic markets. The company is actively exploring opportunities to develop and commercialize Speragen in the country, with the goal of making the treatment available to patients and families as quickly as possible.
That focus is not surprising. Japan has a highly developed healthcare system, strong clinical research infrastructure, and a substantial market for innovative therapies in psychiatry and neurology. At the same time, autism spectrum disorder is an area of increasing public health and clinical focus in many countries, including Japan, where awareness, diagnosis, and support needs continue to evolve.
By receiving a major honor from a Japanese psychiatric journal and presenting the work at the annual conference of the Japanese Society of Psychiatry and Neurology, Astrogen has gained a potentially valuable foothold in that market. The recognition can help open doors to academic collaborations, licensing discussions, commercial partnerships, and physician engagement efforts that may support future development activities in Japan.
For a biotech company seeking international expansion, these early relationships and visibility opportunities can be extremely important. They help establish the company as a serious player in the therapeutic area and create a narrative around the product that goes beyond regulatory filings alone. In Astrogen’s case, the combination of scientific recognition, conference exposure, and public statements about Japan’s strategic importance suggests the company is deliberately building momentum toward a broader regional and potentially global commercialization strategy.
Invitation to Contribute Frontier Review Signals Growing Scientific Influence
The impact of Astrogen’s award-winning paper has already extended beyond the prize itself. Following the recognition, the research team was formally invited by the PCN Editorial Committee to contribute a “PCN Frontier Review” article on the latest research trends in autism spectrum disorder.
This invitation is notable because frontier reviews are typically commissioned from experts or research groups whose work is seen as especially relevant to advancing understanding in a given field. By asking Astrogen and its collaborators to write such a review, the editorial committee is effectively acknowledging the team as a meaningful voice in current ASD research.
For Astrogen, this is an opportunity to do more than simply report clinical trial results. A frontier review would allow the company and its academic collaborators to help shape broader scientific discussion around autism treatment, emerging mechanisms, unmet clinical needs, and future directions for research. It also further deepens the company’s relationship with one of the region’s leading psychiatric journals and strengthens its profile as a contributor to the academic discourse surrounding ASD.
From a strategic perspective, this kind of invitation can be almost as valuable as the award itself. It places Astrogen within the ongoing scientific conversation about where autism research is headed, not just as a sponsor of a single study, but as an organization engaged in the long-term advancement of the field.
Broader Implications for Autism Research and Biotech Innovation
Astrogen’s recognition comes against a backdrop of growing global interest in autism research, early intervention, and therapies that can address core symptoms of the disorder. Autism spectrum disorder affects social communication and behavior in ways that can vary widely from one individual to another, creating both clinical complexity and a pressing need for treatments tailored to diverse patient needs.
Despite significant advances in diagnosis and supportive care, the development of pharmacologic interventions for ASD remains challenging. Many existing treatment approaches focus on associated symptoms such as irritability or hyperactivity rather than directly targeting social communication deficits. This is why research into therapies like AST-001 has attracted attention: it represents an effort to address a core functional domain of autism that has major implications for daily life, education, family support, and long-term development.
The Folia Award therefore has meaning not only for Astrogen but for the wider autism research community. It highlights the importance of rigorous clinical trials in pediatric neurodevelopmental disorders and underscores the scientific interest in interventions that move beyond symptom management toward potentially improving social communication outcomes.
For Korean biotechnology as a whole, the award also reflects the increasing international reach of research emerging from the country’s life sciences sector. South Korean biotech companies have become more active in oncology, cell therapy, rare disease, and neuroscience, and Astrogen’s recognition in an international psychiatric journal adds to that broader narrative of scientific globalization.
Astrogen Looks Ahead to the Next Phase of Development
With a major international award now in hand, Astrogen appears to be entering a new phase in the development of Speragen. The company is balancing several priorities at once: awaiting a regulatory decision in South Korea, pursuing strategic development and commercialization opportunities in Japan, expanding its scientific presence through invited publications, and continuing to position AST-001 within the global conversation about autism treatment innovation.
The Folia Award does not guarantee regulatory approval or commercial success, but it does provide a meaningful signal that Astrogen’s work is being taken seriously by respected figures in psychiatry and neuroscience. In an industry where credibility is built step by step—through data, publications, peer recognition, conference visibility, and regulatory progress—this recognition represents a significant milestone.
For families affected by autism spectrum disorder, the company’s long-term goal remains clear: to bring Speragen to patients as quickly as possible if regulatory and clinical pathways continue to support its development. For Astrogen itself, the award offers both validation and momentum as it works to transform an academic achievement into a broader therapeutic and commercial opportunity.
As the company continues advancing its autism program, the Folia Award serves as a reminder that scientific recognition can play a powerful role in elevating promising therapies, strengthening international partnerships, and drawing attention to areas of medicine where new treatment options are urgently needed. Astrogen’s latest milestone suggests that its work in autism research is gaining traction on exactly that kind of global stage.
